immune system
• of pro-B cells from pIpC-treated mice exposed to IL7
|
• of pro-B cells from pIpC-treated mice exposed to IL7
|
• reduced frequency in pIpC-treated mice
|
• reduced in pro-B cells
|
• lower frequency of early (fraction B) and late (fraction C) pro-B cell in pIpC-treated mice
• higher frequency of pre-pro-B cells in pIpC-treated mice
• however, the number of pre-pro-B cells is normal
|
• reduced numbers in pIpC-treated mice
|
• severely decreased numbers in pIpC-treated mice
|
• severely decreased numbers in pIpC-treated mice
|
• at the early stage of B-lineage cells in the bone marrow of pIpC-treated mice
|
• in the bone marrow and spleen of pIpC-treated mice
|
• by half in pIpC-treated mice
|
• reduced frequency in pIpC-treated mice
|
cellular
• of pro-B cells from pIpC-treated mice exposed to IL7
|
• of pro-B cells from pIpC-treated mice exposed to IL7
|
hematopoietic system
• of pro-B cells from pIpC-treated mice exposed to IL7
|
• of pro-B cells from pIpC-treated mice exposed to IL7
|
• reduced frequency in pIpC-treated mice
|
• reduced in pro-B cells
|
• however, the number of pre-pro-B cells is normal
• lower frequency of early (fraction B) and late (fraction C) pro-B cell in pIpC-treated mice
• higher frequency of pre-pro-B cells in pIpC-treated mice
|
• reduced numbers in pIpC-treated mice
|
• severely decreased numbers in pIpC-treated mice
|
• severely decreased numbers in pIpC-treated mice
|
• at the early stage of B-lineage cells in the bone marrow of pIpC-treated mice
|
• pIpC-treated mice exhibit a mild decrease in lymphoid-primed multipotent progenitors compared with control mice
|
• pIpC-treated mice exhibit a reduction in common lymphoid progenitors highly expressing AA4.1/Cd93 compared with control mice
|
• in the bone marrow and spleen of pIpC-treated mice
|
• by half in pIpC-treated mice
|
• reduced frequency in pIpC-treated mice
|